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Pathophysiology of the edema
Diabetic  retinopathy  (DR)  is  the  leading  cause  of  irreversible
blindness  in  people  of  a  productive  age  in  devel-
oped  countries,  macular  edema  being  (DME)  primarily
responsible.1 DME  occurs  through  the  alteration  of  the
blood--ocular  barrier  (BRB),  with  a  multifactorial  mechanism
secondary  to  changes  in  cellular  junctions,  loss  of  pericytes
and  endothelial  cells,  dilation  of  retinal  vessels,  leukosta-
sis  and  vitreoretinal  traction.2,3 In  general,  it  is  due  to  the
increase  in  inﬂammatory  factors,  such  as  prostaglandins  and
speciﬁc  proinﬂammatory  interleukins,  and  angiogenic  sub-
stances  which  include  vascular  endothelial  growth  factor
(VEGF).  Decreases  of  the  anti-angiogenic  retinal  pigment
epithelium  derived-factor  (PEDF)4 also  contribute  to  this
mechanism.
Diagnosis
DME  diagnosis  is  clinically  performed  by  fundoscopy;  when
the  center  of  the  macula  (fovea  centralis)  is  thickened  or
swollen,  this  is  referred  to  as  a  clinically  signiﬁcant  central-
involved  macular  edema  (CI-CSME)  and  when  it  is  unaffected
we  refer  to  is  as  a  clinically  signiﬁcant  non-central-involved
macular  edema  (NCI-CSME).  Fluorescent  angiography  (FAG)∗ Corresponding author at: Av. Madero y Gonzalitos s/n, Colonia
Mitras Centro, C.P. 66460 Monterrey, NL, Mexico.
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lassiﬁes  it  as  focal  and  diffuse,  which  guides  the  patho-
hysiology.  Focal  DME  is  the  result  of  internal  BRB  damage
microaneurisms),  whereas  diffuse  DME  is  linked  mainly  to
xternal  BRB  damage  (pigment  epithelium  of  the  retina).
ome  patients  can  display  DME  with  both  angiographic  pat-
erns.  FAG  remains  the  ‘‘gold  standard’’  when  deciding  DME
reatment;  nevertheless,  in  a  publication  about  the  value
f  FAG  in  the  planning  of  DME  treatment,  we  found  that
he  capability  of  the  specialist  to  decide  the  treatment  with
aser  after  photographic  analysis  without  FAG  matched  with
he  analysis  based  on  FAG  in  85.7%  of  cases  and  showed  slight
ariations  between  both  analyses  in  14.3%.5 Despite  the  fact
hat  FAG  is  very  useful  clinically,  it  does  not  contributes  that
uch  to  the  evaluation  of  retinal  morphology  and  its  thick-
ning  pattern.  In  1991,  the  optical  coherence  tomography
OCT)  was  patented,  and  nowadays  is  an  essential  com-
lement  to  the  ophthalmoscopy  and  FAG  in  patients  with
ME.  OCT  is  currently  the  most  precise  technique  for  in  vivo
easurement  of  retinal  thickness  and  the  analysis  of  vitreo-
acular  interface,  being  key  in  diagnosis  and  monitoring  of
reatment.
reatment
reatment  is  focused  on  reestablishing  BRB,  modulating
nﬂammatory  and  angiogenic  factors.  The  Early  Treatment
iabetic  Retinopathy  Study  (ETDRS)  proved  there  was  a
eduction  of  50%  in  the  risk  of  moderate  vision  loss  when
reating  the  edema  with  a  threshold  laser  (from  24%  to
2%  at  3  years),  increasing  the  possibility  of  obtaining  a
asson Doyma Me´xico S.A. This is an open access article under the
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light  visual  improvement.  However,  in  diffuse  DME  this
mprovement  is  limited.  Recently,  the  use  of  vascular  growth
actor  antagonists  (anti-VEGFs)  in  intravitreal  injections
as  proven  to  reduce  neurovascularization  and  DME,  with
etter  results  than  laser  monotherapy  (REVEAL,  RESTORE,
IVID,  VISTA,  DA  VINCI,  BOLT,  etc.).  The  laser  acts  as  a
odulator  of  substances  like  PEDF  and  VEGF,  in  addition
o  the  thermal  destruction  of  the  external  layers  of  the
etina,  and  reduces  metabolic  demand  and  oxygen  expen-
iture,  with  the  consequent  reduction  of  VEGF.  Anti  VEGFs
electively  block  VEGF.  Bevacizumab  (BVZ)  (AvastinTM)  is  a
ecombinant  humanized  monoclonal  (IgG1)  antibody  which
nites  all  VEGF-A  isoforms  and  has  been  used  off-label  via
ntravitreal  injection  since  2005  in  different  angioprolif-
rative  pathologies.  Ranibizumab  (RBZ)  (LucentisTM)  is  a
umanized  antibody  fragment  directed  against  all  VEGF-A
soforms,  manufactured  exclusively  for  its  intravitreal  use.
anibizumab  was  approved  by  the  FDA  in  2012,  and  by
he  Federal  Commission  for  the  Protection  of  Sanitary  Risks
COFEPRIS  by  its  Spanish  acronym)  in  2014,  for  its  intraoc-
lar  use  in  DME  treatment.  Aﬂibercept  (AFB)  (EyleaTM in
SA/WetliaTM in  Mexico)  is  a  recombinant  fusion  protein,
onsisting  of  fractions  of  domains  of  the  human  recep-
ors  of  VEGF  type  1  and  2.  It  attaches  to  VEGF-A  and  the
lacental  Growth  Factor  (PGF)  in  a  sort  of  ‘‘bait  recep-
or’’,  avoiding  its  interaction  with  native  VEGF  receptors.
t  has  also  been  approved  by  the  FDA  (2014),  and  is  pend-
ng  approval  by  COFEPRIS  (by  the  end  of  2015)  for  its
ntravitreal  use  in  DME.  Multiple  studies  have  proven  the
afety  and  efﬁcacy  of  these  anti-VEGFs  (ANCHOR,  MARINA,
IER,  PrONTO,  SUSTAIN,  SAILOR,  HORIZON,  READ,  RISE,  RIDE,
ESOLVE,  RESTORE,  CATT,  COPERNICO,  GALILEUS,  DA  VINCI,
IVID,  VISTA,  BOLT,  DRCRnet,  etc.).  In  2011,  the  CATT  study
roved  the  safety  and  efﬁcacy  of  RBZ  as  well  as  BVZ  in  the
reatment  of  wet-age  related  macular  degeneration  (angio-
roliferative  disease).  Neither  were  statistically  superior
safety  and  efﬁcacy)  to  the  other.  This  study  supported  the
ases  to  continue  the  off-label  use  of  intravitreal  BVZ.  In
arch  2015,  the  DRCnet  published  the  results  of  their  study,
‘Protocol  T’’.  The  study  compared  the  safety  and  efﬁcacy
f  these  anti-VEGFs  in  DME.  It  reported  an  improvement
n  visual  acuity  in  patients  with  central-involved  macular
dema,  but  this  effect  depended  on  the  initial  visual  acu-
ty.  When  initial  visual  acuity  loss  was  minor  (20/30  to
0/40),  on  average,  there  were  no  apparent  differences
etween  the  3  anti-VEGFs.  Nevertheless,  in  patients  with
ow  initial  visual  acuity  (20/50  or  worse),  AFB  proved  to
e  more  effective  in  visual  acuity  improvement.  Intra-
itreal  steroids  have  shown  encouraging  results  in  the
reatment  of  DME;  they  inhibit  over-regulation  of  inﬂam-
atory  molecules  and  VEGFs.  There  are  the  dexamethasone
ntravitreal  implant  (OzurdexTM)  and  the  ﬂuocinolone  intra-
itreal  implant  (lluvienTM),  the  ﬁrst  one  approved  by  the
DA  and  pending  approval  by  COFEPRIS  (by  the  end  of
015)  for  its  use  in  DME.  The  latter  has  been  approved
or  its  use  only  in  Europe.  Preservative-free  triamcinolone
ATLCTM)  is  another  steroid  also  approved  by  the  COFEPRIS
or  intraocular  use.  Nowadays,  steroids  are  recommended
or  resistant  cases;  however,  some  ophthalmologists  con-
ider  them  as  a  ﬁrst  line  treatment  or  as  an  adjuvant  therapy
o  laser  and  anti-VEGFs.  Because  the  vitreomacular  inter-
ace  (posterior  hyaloid  and  inner  limiting  membrane)  plays
o
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n  important  role  in  the  development  of  DME,  in  tractive  or
on-respondent  cases  its  withdrawal  is  indicated  via  vitrec-
omy.
Different  schemes  in  DME  treatment  have  been
escribed.  Threshold  laser  is  recommended  in  a  selective
ashion  in  a single  use  and,  if  necessary,  repeated  in  inter-
als  of  no  less  than  12  weeks.  Pharmacological  therapy  with
nti-VEGFs  has  been  proposed,  from  having  one  injection
nd  repeating  only  when  the  ophthalmologist  considers  it
ecessary  (Pro  Re  Nata  PRN),  to  uninterruptedly  every  4
eeks  for  24  months  (monthly  dose).  Currently,  there  are
wo  schemes,  ‘‘treat  and  observe’’  (T&O)  and  ‘‘treat  and
xtend’’  (T&E),  the  ﬁrst  one  consists  of  applying  a  ‘‘loading
hase’’  of  three  anti-VEGF  doses  or  until  accomplishing  the
aximum  visual  effect  and  resolution  of  the  edema,  with  a
-week  interval  between  each  injection,  and  after  that  in  a
RN  mode.  In  the  latter  (T&E),  after  the  ‘‘loading  phase’’,
he  treatment  is  extended  in  rows  of  2  weeks  until  achieving
ntervals  no  longer  than  12  weeks.  Re-treatment  or  treat-
ent  extension  criteria  will  depend  on  visual  acuity  and
omography  ﬁndings,  loss  (T&O)  or  non-loss  (T&E)  of  more
han  ﬁve  letters,  or  an  increase  (T&O)  or  decrease  (T&E)  of
acular  thickness  of  over  100  microns.  In  case  of  presenting
dema  reactivation  in  the  scheduled  appointment  (T&E),
 shortened  treatment  is  indicated.  Based  on  the  possible
ynergy  between  laser,  corticosteroids  and  anti-VEGFs,  the
ombination  of  these  three  at  the  same  time  has  been  pro-
osed,  with  two  intentions;  accomplishing  a  greater  visual
nd  anatomical  effect,  and  accomplishing  the  least  amount
f  treatment  repetition  in  the  long  term.  Nowadays,  there
s  no  exact  algorithm  for  DME  treatment,  thus  it  remains  a
ebate  topic  in  retina  conferences.
y personal approach
trict  glycemic  and  lipid  controls,  systemic  blood  pressure
nd  renal  stability  are  fundamental.  I decide  on  the  treat-
ent  depending  on  clinical,  angiographic  and  tomographic
resentations.  Based  on  reports  from  medical  literature,
s  well  as  my  personal  experience,6--8 I consider  as  a  ﬁrst
ine  treatment  laser  or  intravitreal  anti-VEGFs  and  intra-
itreal  steroids  or  vitrectomy  as  a  second  line  treatment.
he  anti-VEGFs  I  use  will  depend  on  the  patient’s  eco-
omic  capabilities;  I  choose  BVZ  in  patients  with  limited
conomic  resources.  Despite  the  fact  that  the  DRCRnet  sug-
ests  a  superiority  of  AFB  in  relation  to  RBZ  in  initial  low
ision  cases,  I  usually  begin  with  RBZ,  and  just  in  case  I
o  not  obtain  a  good  response,  I  switch  to  AFB  or  BVZ.
onotherapy  with  anti-VEGFs,  or  in  combination  with  laser,
n  my  experience,  has  proven  to  be  superior  to  combined
herapy  with  steroids  (TLC)  during  the  ‘‘loading  phase’’.7
herefore  unless  it  is  a  case  of  macular  ischemia  (MI)  or
itreo-proliferative  diabetic  retinopathy  (VPDR),  where  the
aser  (MI)  and  the  anti-VEGFs  (MI  and  VPDR)  may  be  ques-
ionable,  I  utilize  them  as  ﬁrst  option  of  treatment.  In  case
f  chronic  DME  with  little  to  no  response  to  pharmacologi-
al  (anti-VEGFs  or  steroids)  and  laser  treatment,  either  with
r  without  VMI  thickening  and/or  VMTS,  I  indicate  vitrec-
omy  (Fig.  1).  Vitrectomy  is  also  the  ﬁrst  option  treatment
n  ﬁbrovascular  tractive  retinal  detachment  with  macu-
ar  involvement  secondary  to  vitreoproliferative  diabetic
Treatment  of  Diabetic  Macular  Edema  245
tinal
o
p
1
e
f
m
i
n
v
fFigure  1  DME  with  a  thickening  of  the  vitrore
retinopathy.  It  is  important  not  to  confuse  VMI  thickening  or
VMTS  with  a  macular  involvement  tractive  retinal  detach-
ment.  As  I  mentioned  before,  in  this  case  vitrectomy  is  my
ﬁrst  option  of  treatment,  contraindicating  even  the  use  of
anti-VEGFs  due  to  risk  of  ﬁbrosis  with  detachment  exacer-
bation.  I apply  pan-retinal  photocoagulation  if  necessary.
In  case  of  presenting  a  NCI-CSME  with  a  good  visual  acuity
(better  than  20/25),  veriﬁed  through  FAG  as  a  focal  DME
and  an  OCT  showing  a  not  involved  fovea  (Fig.  2),  despite
showing  an  anti-VEGF  superiority  over  laser  treatment  in
my  experience,8 the  decision  to  use  monotherapy  with  laser
as  a  ﬁrst  line  treatment  is  my  choice  (risk  of  complication
with  intravitreal  injection).  Different  from  that  suggested
by  the  ETDRS,  I  use  the  invisible  or  subthreshold  modiﬁed
laser  modality  previously  published,9 with  the  objective
a
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Figure  2  Focal  DME  witho interface  and  vitromacular  traction  syndrome.
f  lowering  the  complications  of  the  threshold  laser.  It  is
ossible  to  repeat  this  therapy  in  intervals  of  no  less  than
2  weeks.  I apply  the  laser  as  a  modiﬁed  ‘‘scatter’’  in  the
dema  zone  (respecting  the  foveolar  center)  and,  differing
orm  multiple  authors  and  the  ETDRS,  never  direct  to
icroaneurisms.9 I  use  anti-VEGFs,  steroids  or  vitrectomy,
n  that  order,  as  rescue  therapies  (when  there  is  a  poor  or
egative  response  with  laser).
In case  of  presenting  a CI-CSME  with  a  slight  decline  in
isual  acuity  (20/30  to  20/40),  veriﬁed  through  FAG  as  a
ocal  DME,  with  leakage  that  extends  to  the  central  zone
nd  an  OCT  showing  foveal  involvement  (Fig.  3),  I suggest  a
ombined  therapy  with  anti-VEGFs  and  subthreshold  lasers
n  the  microaneurism  zone,  respecting  the  foveolar  center.
 apply  the  laser  1--3  weeks  after  the  ﬁrst  injection,  with
ut  foveal  involvement.
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he  objective  of  a  possible  reduction  in  the  frequency  of
uture  re-treatments.  The  injection  scheme  that  I  conduct  is
‘Treat  &  Extend’’.  If  necessary,  I  repeat  the  laser  treatment
ith  intervals  of  no  shorter  than  12  weeks  between  each
ession.  Steroids  and/or  vitrectomy  are  just  in  case  of  a  poor
r  null  response.
In  case  of  presenting  a  CI-CSME  with  a  bad  visual  acu-
ty  (less  than  20/40),  veriﬁed  through  FAG  as  a  diffuse  or
ixed  DME  and  an  OCT  with  foveal  data  either  in  a  bee-
ive  or  petaloid  shape,  or  with  an  added  neurosensorial
etachment  (Fig.  4),  monotherapy  with  anti-VEGFs  under
he  ‘‘Treat  &  Extend’’  scheme  is  what  I  do.  It  is  important
o  stress  that,  despite  having  a  good  response  from  the  ﬁrst
r  second  injection  during  the  ‘‘loading  phase’’,  they  ought
t
a
d
p
Figure  4  Diffuse  DME  with  a  cystic  beehive foveal  involvement.
o  be  repeated  on  at  least  three  occasions  (Fig.  5).  In  case
f  a  partial  response,  I  add  subthreshold  lasers  as  a  rescue
reatment,  with  the  purpose  of  stimulating  the  production
f  PEDF  and  obtaining  (by  stimulation  of  the  epithelium)  a
etter  response  to  anti-VEGFs.  In  case  of  a null  response
ith  anti-VEGFs,  I  do  not  apply  lasers  and  cut  straight  to
teroids.  Given  the  case,  if  the  patient  shows  positive  results
o  the  steroid  therapy,  the  best  is  to  try  to  continue  this
tability  returning  to  anti-VEGFs.  If  this  is  not  possible,  I
epeat  steroid  treatment  at  the  time  of  recurrence.  Similar
o  the  other  cases,  if  there  is  no  response  to  medical  ther-
py  I  perform  a  vitrectomy.  Something  that  may  also  occur,
espite  satisfactory  results  with  an  anti-VEGFs,  is  that  the
atient  may  develop  chronical  tachyphylaxis  or  resistance  to
 pattern  and  neurosensory  detachment.
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Pre ranibizumab
Post 2 aplicaciones ranibizumab
e-  an
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8Figure  5  Diffuse  DME  with  central  involvement,  pr
the  anti-VEGF,  suddenly  manifesting  a  negative  response.  In
this  case,  switching  to  a  different  anti-VEGF  may  reestablish
a  positive  response.
In  summary,  anti-VEGFs  are  currently  the  ‘‘gold
standard’’  in  diffuse  DME  treatment.  Laser  remains  as  the
‘‘gold  standard’’  in  the  treatment  of  focal  DME  without
foveal  involvement.  Likewise,  laser  is  used  as  an  adju-
vant  therapy  to  pharmacological  treatment  (anti-VEGFs  and
steroids).  Steroids  are  used  in  little  or  non-respondent  cases
(with  or  without  VMI  thickening  and/or  VMTS)  resistant  to
ﬁrst  line  treatment  (laser  and  anti-VEGF)  and  as  an  adjuvant
therapy  to  this  same  therapy.  On  the  other  hand,  steroids
may  apply  as  a  ﬁrst  choice  of  treatment  of  ischemic  DME.
A  vitrectomy  is  indicated  in  case  of  chronic  DME  with  lit-
tle  or  no  response  to  pharmacological  and  laser  treatment,
either  with  or  without  VMI  alteration  and/or  VMTS,  and  as
a  ﬁrst  option  of  treatment  in  ﬁbrovascular  tractive  retinal
detachment.
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